CSLの収益は政策の移行と再建に際して88%減少し,投資家の不安や株式の低さが引き起こされたが,同社は全年度の見通しを擁護し,米国生産拡大に150億ドルを約束している. CSL's profit plummeted 81% amid policy shifts and restructuring, triggering investor worry and a stock low, yet the company upheld its full-year outlook and pledged $1.5 billion for U.S. production expansion.

オーストラリア最大のバイオ医薬品会社CSLは,第1回のネット利益の88%が4億100万ドルに低下し,政府政策の変化を示唆し,1回の復興費用と資産の損失を訴えた. CSL, Australia's largest biopharmaceutical company, reported an 81% drop in first-half net profit to $401 million, citing government policy changes, one-off restructuring costs, and asset impairments. 利益は7%減って19億ドルとなりました Underlying profit fell 7% to $1.9 billion. CEOの驚きの引退の発表は,投資家の懸念を巻き起こし,株式を8年低額に送付した. The announcement of its CEO's surprise retirement triggered investor concern, sending shares to an eight-year low. 減収にもかかわらず,同社は全年指導を継続し,国内生産拡大に15億ドルの投資を発表した. Despite the downturn, the company maintained its full-year guidance and announced a $1.5 billion U.S. investment to expand domestic production.